Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lance-And-Sensor Combo Device Could Be Available To U.S. Diabetics In 2007

This article was originally published in The Gray Sheet

Executive Summary

Pelikan Technologies says its purchase of Inventus BioTec puts the company on track to obtain 510(k) clearance for a fully integrated lance and glucose monitor in 2006, with a U.S. launch the next year

You may also be interested in...



Pelikan Sun

Electronically controlled, fully automated lancing system will be unveiled at the June American Diabetes Association Scientific Sessions in New Orleans. Designed to reduce pain associated with blood sample collection, the device will launch in "early 2004" in the U.S., Pelikan Technologies says. The firm gained 510(k) clearance April 23. A second-generation system that combines the lancet with glucose measurement capability is expected in 2005...

PBA Announces New Leadership; Honest Company Names CFO; Beauty Executive News

Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.

Biden Aims For 200 Mil. More COVID Vaccine Doses As Nervous Europe Eyes Its Borders

New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel